Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Rog

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Immunobiology|June 15, 2010
Cannabis-based medicines in multiple sclerosis--a review of clinical studiesDavid J Rog
Multiple Sclerosis and Related Disorders|December 3, 2023
Ethnic disparities in the epidemiological and clinical characteristics of multiple sclerosisGagana Mallawaarachchi, David J Rog, Joyutpal Das
Clinical Therapeutics|November 24, 2007
Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trialDavid J Rog, Turo J Nurmikko, Carolyn A Young
The Clinical Journal of Pain|June 19, 2007
Validation and reliability of the Neuropathic Pain Scale (NPS) in multiple sclerosisDavid J Rog, Turo J Nurmikko, Tim Friede, et al.
Neurology|September 28, 2005
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosisDavid J Rog, Turo J Nurmikko, Tim Friede, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 17, 2024
University education facilitates uptake of disease-modifying therapies for multiple sclerosis: A community-based study using the UK MS RegisterJoyutpal Das, David J Rog, Rod Middleton, et al.
Multiple Sclerosis and Related Disorders|January 5, 2022
The association between deprivation and the access to disease modifying therapies for multiple sclerosis: An England wide community-based study in the UK MS RegisterJoyutpal Das, David J Rog, Rod Middleton, et al.
Multiple Sclerosis and Related Disorders|November 6, 2023
Multiple Sclerosis vision questionnaire (MSVQ-7): Reliability, validity, precision and discriminationCarolyn A Young, David J Rog, Radu Tanasescu, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 17, 2023
Correlates and trajectories of relapses in relapsing-remitting multiple sclerosisCarolyn A Young, David J Rog, Basil Sharrack, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 17, 2023
Measuring disability in multiple sclerosis: the WHODAS 2.0Carolyn A Young, David J Rog, Basil Sharrack, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Immunobiology|June 15, 2010
Cannabis-based medicines in multiple sclerosis--a review of clinical studiesDavid J Rog
Multiple Sclerosis and Related Disorders|December 3, 2023
Ethnic disparities in the epidemiological and clinical characteristics of multiple sclerosisGagana Mallawaarachchi, David J Rog, Joyutpal Das
Clinical Therapeutics|November 24, 2007
Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trialDavid J Rog, Turo J Nurmikko, Carolyn A Young
The Clinical Journal of Pain|June 19, 2007
Validation and reliability of the Neuropathic Pain Scale (NPS) in multiple sclerosisDavid J Rog, Turo J Nurmikko, Tim Friede, et al.
Neurology|September 28, 2005
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosisDavid J Rog, Turo J Nurmikko, Tim Friede, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 17, 2024
University education facilitates uptake of disease-modifying therapies for multiple sclerosis: A community-based study using the UK MS RegisterJoyutpal Das, David J Rog, Rod Middleton, et al.
Multiple Sclerosis and Related Disorders|January 5, 2022
The association between deprivation and the access to disease modifying therapies for multiple sclerosis: An England wide community-based study in the UK MS RegisterJoyutpal Das, David J Rog, Rod Middleton, et al.
Multiple Sclerosis and Related Disorders|November 6, 2023
Multiple Sclerosis vision questionnaire (MSVQ-7): Reliability, validity, precision and discriminationCarolyn A Young, David J Rog, Radu Tanasescu, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 17, 2023
Correlates and trajectories of relapses in relapsing-remitting multiple sclerosisCarolyn A Young, David J Rog, Basil Sharrack, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 17, 2023
Measuring disability in multiple sclerosis: the WHODAS 2.0Carolyn A Young, David J Rog, Basil Sharrack, et al.
Pageof 2